Drug Trial Radar · NCT02850406
Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
147
Actual
Start
Jul 5, 2016
Primary completion
Oct 2, 2023
Study completion Oct 2, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 1, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study consists of four parts, Parts A, B, C, and D. * Part A is a single dose pharmacokinetic (PK) study in pediatric participants with Sickle Cell Disease ages 6 to 17 years. * Part B is a multiple dose, safety, exploratory, efficacy, and PK study in adolescent participants with Sickle Cell Disease ages 12 to 17 years. * Part C is a multiple dose, safety, tolerability, and PK study, which includes the assessment of hematological effects and the effect on TCD flow velocity of voxelotor in pediatric participants with Sickle Cell Disease ages 4 to 17 years. * Part D is a multiple dose, safety, tolerability, and PK study, which examines the hematological effects of voxelotor in pediatric participants with Sickle Cell Disease ages 6 months to \< 4 years.
Conditions
- Sickle Cell Disease
Interventions
VoxelotorDrug
* Part A: Voxelotor will be administered as oral capsules or tablets * Part B: Voxelotor will be administered as oral capsules or tablets * Part C: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension * Part D: Voxelotor will be administered as oral dispersible tablets or powder for oral suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Maximum Concentration (Cmax) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96, 168 and 336 hours post-dose
- Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96, 168 and 336 hours post-dose
- Part A: Area Under the Concentration-Time Curve (AUC) From Time 0 Extrapolated to Infinity (AUC0-inf) of Voxelotor in Whole BloodTime frame: pre-dose, 2, 8, 24, 48, 96,168 and 336 hours post-dose
- Part B: Change From Baseline to Week 24 in Hemoglobin LevelTime frame: Baseline, Week 24
- Part C: Change From Baseline to Week 48 in Cerebral Blood FlowTime frame: Baseline, Week 48
- Part D: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From start of study treatment up to 28 days after study treatment discontinuation (Up to 52 weeks)
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Brentwood Clinic UCSF Benioff Children's Hospital Oakland
Brentwood, California
Children's National Medical Center
Washington D.C., District of Columbia
Children's Healthcare of Atlanta Scottish Rite
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Illinois at Chicago Clinical Research Center
Chicago, Illinois
Our Lady of the Lake Children's Hospital (IP Address)
Baton Rouge, Louisiana
Children's Mercy Hospital
Kansas City, Missouri
Rutgers-Robert Wood Johnson Medical School
New Brunswick, New Jersey
Brody School of Medicine at East Carolina University
Greenville, North Carolina
University Hospitals Cleveland Medical Center, Rainbow Babies & Children's Hospital
Cleveland, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
St. Jude Children's Research Hospital
Memphis, Tennessee
American University of Beirut - Medical Center
Beirut, Lebanon
Rafik Hariri University Hospital
Beirut, Lebanon
Nini Hospital
Tripoli, Lebanon
Barts Health NHS Trust, The Royal London Hospital
London, United Kingdom
Guy's and St Thoma's NHS Foundation Trust, Evelina London Children's Hospital
London, United Kingdom
Manchester University NHS Foundation Trust, Royal Manchester Children's Hospital
Manchester, United Kingdom
University College London Hospital, NHS Foundation Trust
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.